These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 923330)

  • 1. Elimination of para-aminosalicylic acid in patients with liver disease and renal insufficiency.
    Held H; Fried F
    Chemotherapy; 1977; 23(6):405-15. PubMed ID: 923330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P-aminosalicylate metabolism in cancer patients sensitive and resistant to chemotherapy.
    Lavigne JG; Barry A; d'Auteuil C; Delage JM
    Br J Cancer; 1977 May; 35(5):580-6. PubMed ID: 577182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic evaluation of para-aminosalicylic acid granules.
    Peloquin CA; Henshaw TL; Huitt GA; Berning SE; Nitta AT; James GT
    Pharmacotherapy; 1994; 14(1):40-6. PubMed ID: 8159600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease.
    Kirch W; Rose I; Demers HG; Leopold G; Pabst J; Ohnhaus EE
    Clin Pharmacokinet; 1987 Aug; 13(2):110-7. PubMed ID: 2887325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A micro-method for the determination of paraaminosalicylic acid (aminosallyl) PAS and n-acetyl-para-aminosalicylic acid (acetyl-PAS).
    NIELSEN E; PRAETORIUS E
    Scand J Clin Lab Invest; 1952; 4(4):313-8. PubMed ID: 13048610
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacokinetics of Para-Aminosalicylic Acid and Its 2 Major Metabolites: A Potential Relationship to the Development of Gastrointestinal Intolerance.
    Adams KT; Donald PR; Abulfathi AA; Diacon AH; Stander MA; Reuter H
    J Clin Pharmacol; 2020 Apr; 60(4):489-494. PubMed ID: 31682027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacokinetics of isoniazid, PAS, and cycloserin in acute and chronic alcoholic intoxication (experimental study)].
    Ortenberg ZA
    Probl Tuberk; 1978 Sep; (9):60-4. PubMed ID: 568263
    [No Abstract]   [Full Text] [Related]  

  • 8. Brain regional pharmacokinetics of p-aminosalicylic acid and its N-acetylated metabolite: effectiveness in chelating brain manganese.
    Hong L; Jiang W; Pan H; Jiang Y; Zeng S; Zheng W
    Drug Metab Dispos; 2011 Oct; 39(10):1904-9. PubMed ID: 21768272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics of the antituberculosis drugs.
    Holdiness MR
    Clin Pharmacokinet; 1984; 9(6):511-44. PubMed ID: 6391781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model.
    Stoeckel K; Koup JR
    Am J Med; 1984 Oct; 77(4C):26-32. PubMed ID: 6093514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of hepatic and renal disorders on the pharmacokinetics of sulfachloropyridacine.
    Mariño EL; Dominguez-Gil A; Tabernero JM; Macias JG
    Int J Clin Pharmacol Ther Toxicol; 1980 Jan; 18(1):10-4. PubMed ID: 7364528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Concentration and excretion of isoniazid and PAS in patients with tuberculosis depending on the functional status of the kidney].
    Savula MM; Kiselova ES
    Vrach Delo; 1978 May; (5):119-22. PubMed ID: 676253
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of sodium para-aminosalicylate on oxygen affinity in normal, sickle and fetal human blood.
    Laasberg LH; Hedley-Whyte J; Laver MB
    J Pharmacol Exp Ther; 1976 Nov; 199(2):441-53. PubMed ID: 10430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elimination and serum protein binding of phenylbutazone in patients with renal insufficiency.
    Held H; Enderle C
    Clin Nephrol; 1976 Sep; 6(3):388-93. PubMed ID: 136326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and protein binding of cefpiramide in patients with alcoholic cirrhosis.
    Demotes-Mainard F; Vinçon G; Amouretti M; Dumas F; Necciari J; Kieffer G; Begaud B
    Clin Pharmacol Ther; 1991 Mar; 49(3):263-9. PubMed ID: 2007321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HPLC analysis of para-aminosalicylic acid and its metabolite in plasma, cerebrospinal fluid and brain tissues.
    Hong L; Jiang W; Zheng W; Zeng S
    J Pharm Biomed Anal; 2011 Apr; 54(5):1101-9. PubMed ID: 21159459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma protein binding of clonazepam in hepatic and renal insufficiency and after hemodialysis.
    Pacifici GM; Viani A; Rizzo G; Carrai M; Rane A
    Ther Drug Monit; 1987 Dec; 9(4):369-73. PubMed ID: 3424402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of various types of liver diseases on the behavior of cefoperazone].
    Malè PJ; Dayer P; Châtelain G; Rudhardt M; Fabre J
    Schweiz Med Wochenschr; 1983 Dec; 113(49):1860-3. PubMed ID: 6676938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioavailability and elimination of digitoxin in patients with hepatorenal insufficiency.
    Kirch W; Ohnhaus EE; Dylewicz P; Pabst J; Storstein L
    Am Heart J; 1986 Feb; 111(2):325-9. PubMed ID: 3946177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal failure after intravenous para-aminosalicylic acid administration in a case of intestinal and renal amyloidoidosis.
    HAGELSTAM L; KUHLBACK B; RISKA N
    Scand J Clin Lab Invest; 1963; 15 Suppl 69():62-9. PubMed ID: 13951868
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.